If you have been reading about Fragment designation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Camouflage does not always fool a predator. When caught out, snake species adopt different defensive tactics and use a complicated set of behaviors when attacked. Some species, like cobras or hognose snakes, first elevate their head and spread out the skin of their neck in an effort to look large and threatening. Failure of this strategy may lead to other measures practiced particularly by cobras, vipers, and closely related species, which use venom to attack. The venom is modified saliva, delivered through fangs from a venom gland. Some non-venomous snakes, such as American hognose snakes or European grass snake, play dead when in danger; some, including the grass snake, exude a foul-smelling liquid to deter attackers.
In 1982, founder Arch "Beaver" Aplin was a partner in the opening of a store in Clute, Texas, the first to bear the name "Buc-ee's". He formed the name Buc-ee's by combining his childhood nickname and the name of his Labrador Retriever, Buck; as well as the appeal of Ipana toothpaste's animated mascot, Bucky the beaver. Aplin was born in Southeast Texas. His father was born in Harrisonburg, northeast of Alexandria, Louisiana, where Arch's grandparents still lived as of 2019. Buc-ee's eventually expanded and opened its first travel center in Luling in 2003. In 2012, Buc-ee's opened its largest travel center in New Braunfels, Texas, on Interstate 35. The New Braunfels location was the largest convenience store in the world at 68,000 square feet (6,300 m2), but on June 26, 2023, the Sevierville, Tennessee, Buc-ee's opened, becoming the world's largest convenience store at 74,707 square feet (6,940.5 m2). The Sevierville store was narrowly surpassed in size by a new store in Luling, Texas, at 75,000 square feet (7,000 m2) on June 10, 2024, replacing the original Luling travel center, which was 35,000 square feet (3,300 m2). The New Braunfels location had the 2012 "Best Restroom in America" as named by Cintas. After significant expansion in the Greater Houston area and central Texas, the first Buc-ee's in the Dallas–Fort Worth metroplex opened in Terrell, Texas, on June 22, 2015. The travel center is three miles (4.8 km) west of the Shops at Terrell, a former Tanger Outlets center, on Interstate 20.
=== Affordable Care Act === Schmitt filed lawsuits to have the Affordable Care Act invalidated by courts. After Missouri voters approved a constitutional amendment to expand Medicaid coverage in the state, he argued that Republican lawmakers and Governor Mike Parson could legally refuse to implement the expansion. The Missouri Supreme Court rejected that position in a 2021 ruling.
== External links == Media related to Phyllostachys nigra at Wikimedia Commons Data related to Phyllostachys nigra at Wikispecies "Phyllostachys nigra". Integrated Taxonomic Information System. John Lindley (1835). "Description of Bambusa nigra". The Penny Cyclopædia of the Society for the Diffusion of Useful Knowledge. Vol. 3. p. 357.
The many-worlds interpretation is discussed by high-level avout at evening meals to which Erasmas performs the duties of a servant. It is hinted that Laterre is a futuristic Earth, which serves as a 'higher plane of existence' for Urnud and Tro, and Arbre is itself a 'higher plane' for Laterre and Fthos. Through observation and experiment, Erasmas and his companions determine that the conference has been infiltrated by the aliens and unmask a French-speaking Laterran linguist named Jules Verne Durand. He explains that the aliens are experiencing internal conflict between two factions. The currently ruling faction (the more militaristic 'lower worlds' Urnud and Tro, as well as some Laterrans) intends to attack and raid Arbre for its resources in order to repair their spaceship, while the opposing faction ('the higher world' Fthos and most Laterrans) favors open negotiation. Durand believes that an alliance could be formed between Arbre and the peaceful faction and offers to help the Arbrans. Fearing alien attack after Durand has been exposed, the avout simultaneously evacuate all concents including Saunt Tredegarh. Erasmas and his comrades are taken to a distant sanctuary where they undergo astronaut training for a mission to board the alien ship, disable its weaponry and negotiate with the aliens. Prior to launch and without their knowledge, the Sæcular Power implants each of them with miniaturized neutron bombs that will be used to kill everyone aboard the alien ship if the mission fails. Three people, including Fraa Jad, are issued detonators.
Sources: en.wikipedia.org
== Career == Following his PhD, Uhlmann moved to the Research Institute of Molecular Pathology in Vienna for postdoctoral research with Kim Nasmyth. In 2000, he established a laboratory at the Imperial Cancer Research Fund (now Cancer Research UK) in London, which ultimately became part of the Francis Crick Institute.
2 parts bai zhi (Chinese:白芷，Angelica dahurica); 2 parts cao wu (Chinese:草烏，Aconitum sp., monkshood or wolfsbane); 2 parts chuān ban xia (Pinellia ternata); 2 parts chuān xiōng (Ligusticum wallichii, Cnidium rhizome, Cnidium officinale or Szechuan lovage); 2 parts dong quai (Angelica sinensis or female ginseng); 1 part tian nan xing (Arisaema rhizomatum or cobra lily) 8 parts yang jin hua (Datura stramonium, Korean morning glory, thorn apple, jimson weed, devil's trumpet, stinkweed, or locoweed). The active ingredients in tsūsensan are scopolamine, hyoscyamine, atropine, aconitine and angelicotoxin. When consumed in sufficient quantity, tsūsensan produces a state of general anesthesia and skeletal muscle paralysis. Shutei Nakagawa (1773–1850), a close friend of Hanaoka, wrote a small pamphlet titled "Mayaku-ko" ("narcotic powder") in 1796. Although the original manuscript was lost in a fire in 1867, this brochure described the current state of Hanaoka's research on general anesthesia. On 13 October 1804, Hanaoka performed a partial mastectomy for breast cancer on a 60-year-old woman named Kan Aiya, using tsūsensan as a general anaesthetic. This is generally regarded today as the first reliable documentation of an operation to be performed under general anesthesia. Hanaoka went on to perform many operations using tsūsensan, including resection of malignant tumors, extraction of bladder stones, and extremity amputations. Before his death in 1835, Hanaoka performed more than 150 operations for breast cancer.
==== Public events ==== In September 1951, Adorno returned to the United States for a six-week visit, during which he attended the opening of the Hacker Psychiatry Foundation in Beverly Hills, met Leo Löwenthal and Herbert Marcuse in New York, and saw his mother for the last time. After stopping in Paris, where he met Daniel-Henry Kahnweiler, Michel Leiris, and René Leibowitz, Adorno delivered a lecture entitled "The Present State of Empirical Social Research in Germany" at a conference on opinion research. Here, he emphasized the importance of data collection and statistical evaluation while asserting that such empirical methods have only an auxiliary function and must lead to the formation of theories that would "raise the harsh facts to the level of consciousness." With Horkheimer as dean of the Arts Faculty, then rector of the university, responsibilities for the institute's work fell upon Adorno. At the same time, however, Adorno renewed his musical work: with talks at the Kranichsteiner Musikgesellschaft, another in connection with a production of Ernst Krenek's opera Leben des Orest, and a seminar on "Criteria of New Music" at the Fifth International Summer Course for New Music at Kranichstein. Adorno also became increasingly involved with the publishing house of Peter Suhrkamp, inducing the latter to publish Benjamin's Berlin Childhood Around 1900, Kracauer's writings, and a two-volume edition of Benjamin's writings.
The connection between GSTP inhibition of the pro-apoptotic JNK pathway and the isozyme's overexpression in drug-resistant tumor cells may itself account for the tumor cells' ability to escape apoptosis mediated by drugs that are not substrates of GSTP. Like GSTP, GSTM1 is involved in regulating apoptotic pathways through direct protein–protein interactions, although it acts on ASK1, which is upstream of JNK. The mechanism and result are similar to that of GSTP and JNK, in that GSTM1 sequesters ASK1 through complex formation and prevents its induction of the pro-apoptotic p38 and JNK portions of the MAPK signaling cascade. Like GSTP, GSTM1 interacts with its partner in the absence of oxidative stress, although ASK1 is also involved in heat shock response, which is likewise prevented during ASK1 sequestration. The fact that high levels of GST are associated with resistance to apoptosis induced by a range of substances, including chemotherapeutic agents, supports its putative role in MAPK signaling prevention.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.